| Website | convergencepharma... |
| Category | BioTech |
| Phone | +44 (0)1223 755 501 |
| Employees |
| TOTAL | $35.4M |
| VENTURE FUNDING TOTAL | $35.4M |
| Series A, 10/10 New Leaf Venture Partners Apposite Capital SV Life Sciences | $35.4M |
Convergence Pharmaceuticals is an independent biotechnology company focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company was formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline (“GSKâ€). Convergence Pharmaceuticals has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signaling through modulation of specific ion-channels.
